Clinical Studies on the Efficacy and Safety of Padma 28, a Complex Herbal Formulation from Tibetan Medicine: An Overview

Abstract

Background: Padma 28 is an herbal formula from Tibetan Medicine, which since 35 years has been registered in Switzerland as a drug for the symptoms of circulatory disorders. Over this time, a large body of scientific literature has accumulated. The aim of this article was to give an overview of the clinical studies. Methods: A systematic literature search was done in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CCRCT). The clinical trials found were assessed regarding fields of application, efficacy, and safety, as well as methodological quality and level of evidence. Results: 29 trials (1 meta-analysis, 21 controlled trials, 7 open trials) and 3 retrospective case studies were found. They deal with different indications and include a total of 1,704 verum (of these, 697 children), 333 placebo, and 394 untreated or healthy patients. Dropouts and withdrawals were 2.5 and 3.5 times higher in the placebo than in the verum group, respectively. The highest level of evidence for the use of Padma 28 was found in the indication of intermittent claudication (11 trials). Indications of efficacy were also found in other vascular (6 trials) and different inflammatory diseases (12 trials). Conclusions: The results suggest a favorable safety profile for Padma 28, also in the children examined (41% of the study population). Furthermore, the results show a broad field of applications. According to clinical evidence, Padma 28 has shown to be a safe and effective symptomatic treatment option for atherosclerosis-related diseases such as intermittent claudication. It also seems to have a potential for application in certain chronic inflammatory diseases such as recurrent respiratory tract infections, viral hepatitis, and multiple sclerosis. However, further randomized controlled trials (RCT) are needed to confirm these findings.

Padma 28 bei venösem Ulcus cruris und durch chronisch-venöse Insuffizienz bedingten Ödemen - ein Fallbericht aus der Praxis

“…Klinische Studien zeigen eine Wirksamkeit des Kombinationspräparats Padma 28 bei arteriellen Durchblutungsstörungen, vor allem bei PAVK [4,5]. Das Arzneimittel wird auch bei venösen Störungen, wie schwere Beine und Ödeme, eingesetzt [6,7].…”

Tibetan Medical Paradigms for the SARS-CoV-2 Pandemic

“…12 Korwin-Piotrowska et al 1992Split et al 1998;Exner et al 2006;Melzer et al 2006. 13 Vennos, Melzer, andSaller 2013;Wangchuk et al 2011Wangchuk et al , 2018 Schwabl and van der Valk 2019. For systematic reviews of related clinical research, see Reuter, Weißhuhn, and Witt 2013;Luo et al 2015.…”

The Tibetan herbal medicines Padma 28 and Padma Circosan inhibit the formation of advanced glycation endproducts (AGE) and advanced oxidation protein products (AOPP) in vitro

“…peripheral arterial occlusive disease (PAOD) and angina pectoris, as well as in symptoms of disturbed circulation such as paresthesias, pain and swelling in the extremities and wound healing [12–15]. These symptoms have a special relevance in diabetic patients.…”